Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

Journal Articles

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Jeffrey Marsal, BS, Rahul Banerjee, MD, Chiung-Yu Huang, PhD, Mimi Lo, PharmD, BCPS, BCOP, Vanessa E Kennedy, MD, Shagun Arora, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Sandy W. Wong, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138618

Published: 2020

Journal Articles

Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Angela Lee, PharmD, Frank Oley, Jr., PharmD, Mimi Lo, PharmD, BCPS, BCOP, Richard Fong, PharmD, BCOP, Mary McGann, PharmD, Ila Saunders, PharmD, BCOP, Shanna Block, PharmD, BCOP, Anjlee Mahajan, MD, Tiffany Pon, PharmD, BCPS

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-138635

Published: 2020

Journal Articles

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Rahul Banerjee, MD, Ann Lazar, PhD MS, Lisa Dunn, RN, Jennifer Knoche, RN, Kelly Jean Brassil, PhD MA, MSN, RN, Dhiren Patel, PharmD, Lindsey Jackson, MPH, CPH, Mimi Lo, PharmD, BCPS, BCOP, Anand Dhruva, MD, Shagun Arora, MD, Sandy W. Wong, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-134163

Published: 2020

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Derek Galligan, MD, Rupa Narayan, MD, Sarah Kim, PharmD, Ann Lazar, PhD MS, Marisela Tan, PharmD, Richard Fong, PharmD, Mimi Lo, PharmD, Nina Shah, MD, Shagun Arora, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD

Blood (2018) 132 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2018-99-111625

Published: 2018

Journal Articles

Frequency, Risk Factors and Mortality Effect of Venous Thromboembolism in Adult Patients with Central Nervous System Lymphoma

Anjlee Mahajan, MD, Son Ho, PharmD, Mimi Lo, PharmD, James L. Rubenstein, MD PhD, Richard Fong, PharmD

Blood (2015) 126 (23): 4458.

https://doi.org/10.1182/blood.V126.23.4458.4458

Published: 2015

NARROW

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Frequency, Risk Factors and Mortality Effect of Venous Thromboembolism in Adult Patients with Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Frequency, Risk Factors and Mortality Effect of Venous Thromboembolism in Adult Patients with Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only